Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest IMS Health Stories

2013-11-21 12:28:29

World's Largest Global mHealth Conference and Expo Brings Together Innovators, Developers, Providers, Payers, Business Leaders and Policymakers WASHINGTON, Nov. 21, 2013 /PRNewswire/ -- The 5(th) Annual mHealth Summit, set to open in three weeks on December 8, will bring together 5,000 health and technology influencers, developers, policy makers and business leaders across the mHealth ecosystem, offering a glimpse at the latest in mobile and wireless health technology developments, policies,...

2013-11-18 08:28:12

- Company awarded 180 days marketing exclusivity - PITTSBURGH, Nov. 18, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Dexmethylphenidate Hydrochloride Extended-release (ER) Capsules, 30 mg, which is the first generic version of Novartis' Focalin XR(®). Mylan was the first company to have filed a substantially complete Abbreviated New Drug Application (ANDA) containing a Paragraph IV patent certification for...

2013-11-11 08:27:48

PITTSBURGH, Nov. 11, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Rabeprazole Sodium Delayed-release Tablets, 20 mg. Rabeprazole Sodium Delayed-release Tablets are the generic version of Eisai Corporation's Aciphex(®) Tablets, and are indicated for short-term treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease, and for short-term treatment in...

2013-11-11 08:27:44

MUMBAI and BALTIMORE, November 11, 2013 /PRNewswire/ -- Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has launched its generic Rabeprazole Sodium delayed-release tablets, 20mg. Lupin had earlier received final approval from the US FDA for the same. Lupin's Rabeprazole Sodium delayed-release tablets, 20mg, are the generic equivalent of Eisai Inc.'s Aciphex(R) delayed-release tablets, 20mg, and are indicated...

2013-11-01 12:27:40

-Expects to be eligible for 180 days of marketing exclusivity- PITTSBURGH, Nov. 1, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has been sued by Teijin Limited, Teijin Pharma Limited and Takeda Pharmaceuticals U.S.A., Inc., in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Febuxostat Tablets, 40 mg and 80 mg. This product is the...

2013-10-22 12:29:10

MUMBAI, India and BALTIMORE, October 22, 2013 /PRNewswire/ -- Pharma Major Lupin Limited (Lupin) announced today that it has received final approval for its supplemental New Drug Application (sNDA) for Antara(R) (Fenofibrate) capsules, 30 mg & 90 mg strengths from the United States Food and Drug Administration (FDA). Lupin Pharmaceuticals Inc. (LPI), the company's US subsidiary, will commence marketing the product shortly. LPI currently markets and promotes Antara(R)...

2013-10-03 12:25:56

MUMBAI, India and BALTIMORE, October 3, 2013 /PRNewswire/ -- Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals, Inc. (LPI), has launched its generic Gatifloxacin Ophthalmic Solution, 0.5%. Lupin had earlier received final approval from the United States Food and Drugs Administration (US FDA) to market a generic version of Allergan Inc.'s Zymaxid(TM) Ophthalmic Solution, 0.5%. Lupin's Gatifloxacin Ophthalmic solution 0.5% is...

2013-10-02 08:30:47

Healthcare Industry Veterans, Ezra Ernst and Gerhard Gallwitz, Join Treato Management Team to Accelerate Company US Growth YEHUD, Israel, October 2, 2013 /PRNewswire/ -- Treato, the source of "patient voice" intelligence from across the social web, today announced the appointment of healthcare industry veterans, Ezra Ernst and Gerhard Gallwitz, to its management team as Chief Commercial Officer and Senior Vice President, Product Strategy and Alliances, respectively....

2013-09-30 08:28:53

- Company awarded 180 days marketing exclusivity - PITTSBURGH, Sept. 30, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Voriconazole for Oral Suspension, 40 mg/mL, which is the first generic version of Pfizer's VFEND(®) for Oral Suspension. Mylan was the first company to have filed a substantially complete ANDA containing a Paragraph IV patent certification for Voriconazole for Oral Suspension, 40 mg/mL. The...

2013-09-25 08:30:29

-Expects to be eligible for 180 days of marketing exclusivity- PITTSBURGH, Sept. 25, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that the company has been sued by Forest Laboratories Inc., Forest Laboratories Holdings Ltd., and Royalty Pharma Collection Trust in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Milnacipran HCl Tablets 12.5 mg, 25 mg, 50 mg and 100 mg. This product is the...